SCHEMBL10237658

SCHEMBL10237658

Cc1cc2cc(C(F)(F)F)ccc2n1Cc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 4/20 0.52
P2RX3 P56373 3/20 0.48
KCNA3 P22001 2/20 0.45
PTGDR2 Q9Y5Y4 2/20 0.44
DRD2 P14416 1/20 0.44
PPARG P37231 3/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
PTGS2 P35354 1/20 0.41
DRD4 P21917 1/20 0.40
PTGES2 Q9H7Z7 1/20 0.40
GALR3 O60755 1/20 0.40
NR2F2 P24468 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086333 0.84 CCR2 (0.55) CCR2PTGDR2HDAC1HDAC2HDAC8
SCHEMBL6084959 0.81 MEN1 (0.49) CCR2HDAC1HDAC2HDAC8HDAC6
SCHEMBL13802402 0.80 MAPT (0.47) CCR2PTGDR2PPARGPTGS2
SCHEMBL16818975 0.80 TYMS (0.46) CCR2P2RX3PTGDR2DRD2PPARG
SCHEMBL9959670 0.78 HDAC1 (0.45) CCR2PPARGHDAC1HDAC2HDAC8
SCHEMBL9958735 0.78 KDM4E (0.50) CCR2HDAC1HDAC2HDAC8HDAC6
SCHEMBL9958540 0.78 BRD4 (0.48) CCR2HDAC1HDAC2HDAC8HDAC6
SCHEMBL9959205 0.78 MEN1 (0.56) CCR2HDAC1HDAC2HDAC8HDAC6
SCHEMBL6823866 0.78 CCR2 (0.52) CCR2PTGDR2HDAC1HDAC2HDAC8
SCHEMBL9959873 0.77 DRD2 (0.46) CCR2PTGDR2DRD2HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9657012-B2 FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. (US) 2017-05-23 US disclosed
US-9657012-B2 FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. (US) 2017-05-23 US disclosed
EP-2655356-B1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS INC (US) 2016-08-03 EP disclosed
EP-2655356-B1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS INC (US) 2016-08-03 EP disclosed
CN-103502237-B Faah inhibitor IRONWOOD PHARMACEUTICALS, INC. (US) 2016-01-20 CN disclosed
US-20150175599-A1 FAAH Inhibitors IRONWOOD PHARMACEUTICALS, INC. (US) 2015-06-25 US disclosed
CN-103502237-A FAAH inhibitors IRONWOOD PHARMACEUTICALS INC 2014-01-08 CN disclosed
WO-2012088469-A1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS, INC. (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175599-A1 FAAH Inhibitors FAAH, FAAH2, ASAH1 CCR2 2914/4885P2RX3 508/4885KCNA3 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.